Helixmith Obtains Patent for 'Anti-Sialyl Tn Chimeric Antigen Receptor'

[Asia Economy Reporter Minwoo Lee] Helixmith announced on the 17th that it has obtained a Japanese patent for 'Anti-Sialyl Tn Chimeric Antigen Receptors (ANTI-SIALYL TN CHIMERIC ANTIGEN RECEPTORS)'.

The company stated, "This pertains to anti-sialyl Tn chimeric antigen receptors for adoptive cell therapy targeting cancers expressing the sialyl Tn antigen (STn) on the TAG-72 (tumor associated glycoprotein 72) glycoprotein, the cells expressing these receptors, and compositions thereof," adding, "It can be utilized in the development of anticancer gene cell therapies for solid tumors such as colorectal cancer, ovarian cancer, gastric cancer, breast cancer, esophageal cancer, bladder cancer, lung cancer, and pancreatic cancer where TAG-72 is expressed."